Profile of:

Robert Landewé


Robert Landewé is a professor of rheumatology at the Academic Medical Center / University of Amsterdam, The Netherlands, and is chair of the department of rheumatology at Zuyderland Medical Center Heerlen, The Netherlands. Professor Landewé received his medical degree from Maastricht University in 1990, and defended his thesis on cyclosporine therapy in rheumatoid arthritis in 1994 in Leiden. He received practical training in general internal medicine and rheumatology at Atrium Medical Center, Heerlen and in rheumatology at the University Hospital, Maastricht. He practices rheumatology in the Zuyderland Medical Center in Heerlen/Sittard, The Netherlands Currently, Professor Landewé is involved in outcome research and epidemiological research in the field of rheumatoid arthritis, spondyloarthritis and other rheumatic & musculoskeletal manifestations. He has extensive experience in the design and analysis of clinical trials and has a special interest in medical statistics. Professor Landewé has authored or co-authored more than 700 articles and many book chapters covering a variety of topics, but with an emphasis on clinical epidemiology, methodology, statistics and guideline development (‘meta-research’). Recently he has developed an interest in -and published about- worldwide equity-issues pertaining to rheumatic diseases, as well as overdiagnosis and overtreatment. He has led many EULAR recommendation initiatives on the management of systemic sclerosis, early arthritis, rheumatoid arthritis, axial spondyloarthritis, and recently on the management of SARS-CoV-2 in patients with inflammatory rheumatic diseases. He is a regular reviewer for several general medicine-, rheumatology- and epidemiology journals. Professor Landewé is a previous executive committee member of OMERACT, is board member and past-president of the Assessment in Spondyloarthritis International Society (ASAS), previous executive board member of the Dutch Society of Rheumatology (responsible for quality of care issues), executive board member of the METEOR foundation (monitoring in rheumatology) and chair of the Quality of Care committee of EULAR. He was the scientific chair of EULAR 2018 in Amsterdam.

Full name: Robert Landewé

Current country: Netherlands

Membership level: Full

Type of membership: EC

Number of publications: 8

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. (2023)
https://pubmed.ncbi.nlm.nih.gov/36261247/

Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. (2023)
https://pubmed.ncbi.nlm.nih.gov/36261247/

Role of vertebral corner inflammation and fat deposition on MRI on syndesmophyte development detected on whole spine low-dose CT scan in radiographic axial spondyloarthritis. (2022)
https://pubmed.ncbi.nlm.nih.gov/35803614/

No efficacy of anti-IL-23 therapy for axial spondyloarthritis in randomised controlled trials but in post-hoc analyses of psoriatic arthritis-related ‘physician-reported spondylitis’? (2021)
https://doi.org/10.1136/annrheumdis-2021-221422

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial (2021)
https://doi.org/10.1093/rheumatology/keab758

Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference (2021)
https://doi.org/10.1136/rmdopen-2021-001654

Use of multidimensional composite scores in rheumatology: parsimony versus subtlety (2021)
https://doi.org/10.1136/annrheumdis-2020-216999

What is axial spondyloarthritis? A latent class and transition analysis in the SPACE and DESIR cohorts (2020)
https://doi.org/10.1136/annrheumdis-2019-216516